Melanoma Trial, Recruiting (NCT07148245)

Melanoma Trial, Recruiting NCT07148245 Sponsor: University of California, San Francisco Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT07148245 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years old or older
You must be able to speak and read English
You have been diagnosed with stage IIB, III, or IV melanoma (a type of skin cancer)
You are scheduled to receive at least one immune checkpoint inhibitor treatment (a type of cancer drug that helps the immune system fight cancer) at a University of California San Francisco medical center location
You may also be eligible if you are taking certain targeted therapy drugs for melanoma, such as BRAF or MEK inhibitors (confirm with trial site)
You must be willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You may not be able to join if you are unable to complete all of the requirements of the study (confirm with trial site for details on what this involves)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carolyn Harris, PhD, RN, University of California, San Francisco

Phone: (415) 502-7774

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07148245

Sponsor: University of California, San Francisco

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: (415) 502-7774

More information: https://clinicaltrials.gov/study/NCT07148245

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years old or older
You must be able to speak and read English
You have been diagnosed with stage IIB, III, or IV melanoma (a type of skin cancer)
You are scheduled to receive at least one immune checkpoint inhibitor treatment (a type of cancer drug that helps the immune system fight cancer) at a University of California San Francisco medical center location
You may also be eligible if you are taking certain targeted therapy drugs for melanoma, such as BRAF or MEK inhibitors (confirm with trial site)
You must be willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You may not be able to join if you are unable to complete all of the requirements of the study (confirm with trial site for details on what this involves)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, San Francisco

Registry

ClinicalTrials.gov

Start date

13 October 2025

Est. completion

30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency of symptoms reported over time; Number of distinct symptom profiles identified; Number of risk factors identified with worse symptom profile over time.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov